Switch to:

Latest Guru Trades with PFE

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-03-31 Reduce -40.13%0.48%$29.66 - $32.75 $ 30.49-3%7276622
Joel Greenblatt 2014-03-31 Add 356.54%0.38%$29.66 - $32.75 $ 30.49-3%1014808
Jean-Marie Eveillard 2014-03-31 Reduce -22.77%0.19%$29.66 - $32.75 $ 30.49-3%7866473
John Hussman 2014-03-31 New Buy0.04%$29.66 - $32.75 $ 30.49-3%17000
Vanguard Health Care Fund 2013-12-31 Reduce -43.19%0.91%$28.24 - $32.2 $ 30.49-1%12153122
Charles Brandes 2013-12-31 Reduce -9.32%0.22%$28.24 - $32.2 $ 30.49-1%5767402
Jean-Marie Eveillard 2013-12-31 Add 23.07%0.16%$28.24 - $32.2 $ 30.49-1%10186005
David Dreman 2013-12-31 Reduce -85.73%0.15%$28.24 - $32.2 $ 30.49-1%10163
Joel Greenblatt 2013-12-31 Add 241.71%0.11%$28.24 - $32.2 $ 30.49-1%222280
Ronald Muhlenkamp 2013-12-31 Add 29.15%0.05%$28.24 - $32.2 $ 30.49-1%45129
Donald Yacktman 2013-12-31 Sold Out 0.01%$28.24 - $32.2 $ 30.49-1%0
Ray Dalio 2013-12-31 Add 102.18%0.01%$28.24 - $32.2 $ 30.49-1%110408
Jean-Marie Eveillard 2013-09-30 Add 174.32%0.44%$27.65 - $29.67 $ 30.496%8276410
Vanguard Health Care Fund 2013-09-30 Reduce -10.74%0.27%$27.65 - $29.67 $ 30.496%21393422
Joel Greenblatt 2013-09-30 Add 259.55%0.04%$27.65 - $29.67 $ 30.496%65050
Ray Dalio 2013-09-30 New Buy0.01%$27.65 - $29.67 $ 30.496%54608
Yacktman Fund 2013-06-30 Sold Out 2.65%$27.23 - $31.08 $ 30.495%0
Donald Yacktman 2013-06-30 Reduce -99.74%2.39%$27.23 - $31.08 $ 30.495%41700
Yacktman Focused Fund 2013-06-30 Sold Out 2.21%$27.23 - $31.08 $ 30.495%0
Michael Price 2013-06-30 Reduce -41.38%0.91%$27.23 - $31.08 $ 30.495%347100
Vanguard Health Care Fund 2013-06-30 Reduce -24.15%0.87%$27.23 - $31.08 $ 30.495%23968323
Jean-Marie Eveillard 2013-06-30 Reduce -54.03%0.34%$27.23 - $31.08 $ 30.495%3017033
James Barrow 2013-06-30 Add 4.37%0.12%$27.23 - $31.08 $ 30.495%60830964
George Soros 2013-06-30 Sold Out 0.06%$27.23 - $31.08 $ 30.495%0
Joel Greenblatt 2013-06-30 Reduce -66.69%0.05%$27.23 - $31.08 $ 30.495%18092
Ray Dalio 2013-06-30 Sold Out 0.02%$27.23 - $31.08 $ 30.495%0
David Dreman 2013-06-30 Reduce -21.76%0.02%$27.23 - $31.08 $ 30.495%71097
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Pfizer Inc

Donald Yacktman Comments on Pfizer - Sep 09, 2013

Pfizer (PFE) was removed from the funds due to price appreciation. The company has struggled to grow over time as it has not has not been able to produce enough new drug revenues to offset major patent expirations like Lipitor. Despite the lack of growth, the stock has appreciated significantly, and we do not think it represents a good value at current prices.

From Yacktman Funds' second quarter 2013 commentary.
Check out Donald Yacktman latest stock trades

Top Ranked Articles about Pfizer Inc

Guru Favorites Top GuruFocus Dividend Growers of the Week
During the past week, GuruFocus recognized four companies as dividend growers. In order to be qualified for this list, the company had to:Have a dividend of greater than 3%. Have a strong history of stable and increasing dividends. Maintain Guru ownership. Have a market cap of greater than $10 billion.The following four companies come from various industries and sectors of the market, but they all fit the necessary criteria needed to qualify them as dividend growers.A comparison of the companies’ historical dividend growth:AT&T (T)On June 27, AT&T declared a dividend of $0.46 per share, representing 5.20% dividend yield for the company. This dividend is payable on August 1 to shareholders of the record at the close of business on July 1, 2014.

The company’s historical dividend growth is as follows:- 10-year: 4.40%- 5-year: 2.30%- 3-year: 2.30%AT&T is a communications holding company. Its subsidiaries and affiliates are the providers of AT&T services in the U.S. and internationally. The company holds a portfolio of the nation’s fastest and most reliable 4G LTE network, wireless internet, Wi-Fi and voice and cloud-based services.AT&T’s historical revenue and net income:The analysis on AT&T reports that the company’s price is near a 5-year high, it has issued $12.6 billion in debt over the past three years and its operating income has been in loss over the past three years. On the other hand the analysis also notes that the Piotroski F-Score is high, its dividend yield is near a 2-year high and its P/E, P/S and P/B ratios are all trading at around historical lows.The Peter Lynch Chart suggests that the company is currently undervalued:AT&T has a market cap of $184.3 billion. Its shares are currently trading at around $35.51 with a P/E ratio of 10.40 and a P/S ratio of 1.50. The company had an annual average earnings growth of 4.10% over the past ten years.Lockheed Martin (LMT)On June 26, Lockheed Martin declared a dividend of $1.33 per share, representing 3.20% dividend yield for the company. This dividend is payable on Sept. 26 to shareholders of the record at the close of business on Sept. 2, 2014.

The company’s historical dividend growth is as follows:- 10-year: 20.90%- 5-year: 20.70%- 3-year: 21.90%Lockheed Martin is a security company that is principally engaged in the research, design, development, manufacture, integration, and sustainment of advanced technology systems and products. It also provides a range of management, engineering, technical, scientific, logistic, and information services.Lockheed Martin’s historical revenue and earnings growth:The analysis on Lockheed Martin reports that the company’s revenue has been in decline over the past month, its dividend yield is near a 3-year low and its price is near a 10-year high.The Peter Lynch Chart suggests that the company is currently overvalued:Lockheed Martin has a market cap of $51.02 billion. Its shares are currently trading at around $160.75 with a P/E ratio of 16.50, a P/S ratio of 1.20 and a P/B ratio of 10.50. The company had an annual average earnings growth of 9.90% over the past ten years.GuruFocus rated Lockheed Martin the business predictability rank of 3-star.Pfizer (PFE)On June 26, Pfizer declared a dividend of $0.260 per share, representing 3.40% dividend yield for the company. This dividend is payable on Sept. 3 to shareholders of the record at the close of business on Aug. 1, 2014.

The company’s historical dividend growth is as follows:- 10-year: 1.20%- 5-year: 5.80%- 3-year: 10.10%Pfizer is a global pharmaceutical firm which develops and produces medicines and vaccines for a range of conditions which include areas of immunology, inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain.Pfizer’s historical revenue and net income:The analysis on Pfizer reports that the company’s revenue has been in decline over the past year, the dividend yield is near a 5-year low, the price is near a 5-year high and its operating margin is expanding.The Peter Lynch Chart suggests that the company is currently undervalued:Pfizer has a market cap of $192.19 billion. Its shares are currently trading at around $30.13 with a P/E ratio of 9.60, a P/S ratio of 4.00 and a P/B ratio of 2.70. The company had an annual average earnings growth of 3.40% over the past ten years.GuruFocus rated Pfizer the business predictability rank of 3-star.Freeport-McMoRan Copper & Gold (FCX)On June 25, Freeport-McMoRan declared a dividend of $0.313 per share, representing 3.40% dividend yield for the company. This dividend is payable on Aug. 1 to shareholders of the record at the close of business on July 15, 2014.

The company’s historical dividend growth is as follows:- 10-year: 0.00%- 5-year: 0.00%- 3-year: 40.60%Freeport-McMoRan is a U.S.-based natural resource company with an industry leading global portfolio of mineral assets, significant oil and gas resources and a growing production profile.Freeport-McMoRan’s historical revenue and net income:The analysis on Freeport-McMoRan reports that the company’s asset growth is faster than its revenue growth and its P/S ratio is close to a 2-year low.The Peter Lynch Chart shows that the company is currently undervalued:Freeport-McMoRan Copper & Gold has a market cap of $38.43 billion. Its shares are currently trading at around $37.00 with a P/E ratio of 15.10, a P/S ratio of 1.80 and a P/B ratio of 1.50. The dividend yield for the company is currently sitting at 3.40%.To view a complete list of high yielding dividend stocks found among the gurus’ portfolios, click here.

Try a free 7-day premium membership. Read more...
Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014?
Pfizer (PFE) will release its first quarter 2014 earnings report before the opening bell on Monday, May 5, 2014. Since the company has posted higher than expected earnings over the past three quarters, analysts and investors are looking for the pharmaceutical giant to beat the Street’s estimates once again. Read more...
Pfizer and Lockheed Martin Top Dividend Growers of the Week
During the past week, GuruFocus recognized four companies as dividend growers. In order to be qualified for this list, the company had to: Read more...
AT&T and Pfizer Top GuruFocus Dividend Growers of the Week
During the past week, GuruFocus recognized five companies as dividend growers. In order to be qualified for this list, the company had to:
Read more...
Top Five Guru-Held Health Care Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which health care companies are held by the most gurus. As of the third quarter, the following five health care companies are held by the largest number of gurus. Read more...
Vanguard Health Care Fund Selling Update
The updated portfolio of the Vanguard Health Care Fund lists 92 stocks, four of them new, a total value at $29.45 billion, and a quarter-over-quarter turnover of 4%. The portfolio is weighted with two sectors: health care at 91.5% and consumer defensive at 2.9%. Vanguard Health Care Fund has averaged a return of 24.96% over 12 months and 9.5% over 10 years, according to the GuruFocus Score Board of Gurus. Read more...
GuruFocus' Weekly Dividend Growers Pt. 2
During the past week, GuruFocus recognized 10 companies as dividend growers. In order to be qualified for this list, the company had to: Read more...
Passion and Compassion - Paul Tudor Jones, Sells in Review
Passion and compassion are the two engines that drive "venture philanthropist" Paul Tudor Jones II, founder, chairman and CEO of The Tudor Group. Passion fuels his vocation as a hedge fund trader extraordinaire. As of this month, Jones has amassed a personal fortune of around $3.7 billion, according to Forbes. Compassion clearly energizes his avocation, helping homeless children and the poor. Paul Tudor Jones is the founder of Robin Hood, a charitable organization formed in 1988 to target poverty in New York City. Its board of directors is peopled with a number of Guru billionaire investors. In his 2011 speech at the Robin Hood Heroes Breakfast, Jones outlined the various kinds of poverty, the worst being a poverty of opportunity Americans are facing. Last year, Robin Hood invested $132 million in 210 poverty-fighting programs. Read more...
Pennant Capital Sells in Review
The updated portfolio of value investor Alan Fournier, fund manager of Pennant Capital Management, lists 46 stocks, eight of them new. His portfolio has a total value of $5.57 billion, with a quarter-over-quarter turnover of 15%. Pennant Capital currently invests in technology with a sector weighting of 26.3%, consumer cyclical at 25.3%, healthcare at 8.9% and financial services at 6.8%. Read more...
The Stocks the Most Gurus Sold While the Fewest Bought
A new feature introduced yesterday filters for the net buys of investment gurus – those with the most buys minus sells. The Net Buys S&P 500 screener also tracks the most net sold stocks. According to the screener, the stocks the most gurus discarded while the fewest bought during the second quarter were: Disney (DIS), Pfizer (PFE), AIG (AIG), News Corp. (NWSA) and Goldman Sachs (GS). Read more...
» More Articles for PFE

Ratios

vs
industry
vs
history
P/E(ttm) 9.70
PFE's P/E(ttm) is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.50 vs. PFE: 9.70 )
PFE' s 10-Year P/E(ttm) Range
Min: 7.67   Max: 200.11
Current: 9.7

7.67
200.11
P/B 2.50
PFE's P/B is ranked higher than
75% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. PFE: 2.50 )
PFE' s 10-Year P/B Range
Min: 1.32   Max: 4.55
Current: 2.5

1.32
4.55
P/S 4.02
PFE's P/S is ranked higher than
67% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. PFE: 4.02 )
PFE' s 10-Year P/S Range
Min: 1.72   Max: 6.36
Current: 4.02

1.72
6.36
PFCF 12.10
PFE's PFCF is ranked higher than
96% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 12.10 )
PFE' s 10-Year PFCF Range
Min: 5.02   Max: 35.16
Current: 12.1

5.02
35.16
EV-to-EBIT 14.32
PFE's EV-to-EBIT is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.97 vs. PFE: 14.32 )
PFE' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 69.7
Current: 14.32

7.9
69.7
PEG 2.20
PFE's PEG is ranked higher than
86% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 356.67 vs. PFE: 2.20 )
PFE' s 10-Year PEG Range
Min: 1.14   Max: 584
Current: 2.2

1.14
584
Shiller P/E 17.90
PFE's Shiller P/E is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 17.90 )
PFE' s 10-Year Shiller P/E Range
Min: 8.49   Max: 40.05
Current: 17.9

8.49
40.05
Current Ratio 2.33
PFE's Current Ratio is ranked higher than
70% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. PFE: 2.33 )
PFE' s 10-Year Current Ratio Range
Min: 0.98   Max: 3.18
Current: 2.33

0.98
3.18
Quick Ratio 2.09
PFE's Quick Ratio is ranked higher than
74% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.67 vs. PFE: 2.09 )
PFE' s 10-Year Quick Ratio Range
Min: 0.74   Max: 2.86
Current: 2.09

0.74
2.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.29
PFE's Dividend Yield is ranked higher than
90% of the 452 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. PFE: 3.29 )
PFE' s 10-Year Dividend Yield Range
Min: 1.54   Max: 10.4
Current: 3.29

1.54
10.4
Dividend Payout 0.60
PFE's Dividend Payout is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 0.60 )
PFE' s 10-Year Dividend Payout Range
Min: 0.12   Max: 8.21
Current: 0.6

0.12
8.21
Dividend growth (3y) 10.10
PFE's Dividend growth (3y) is ranked higher than
84% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. PFE: 10.10 )
PFE' s 10-Year Dividend growth (3y) Range
Min: -14.7   Max: 22.6
Current: 10.1

-14.7
22.6
Yield on cost (5-Year) 4.37
PFE's Yield on cost (5-Year) is ranked higher than
90% of the 459 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. PFE: 4.37 )
PFE' s 10-Year Yield on cost (5-Year) Range
Min: 2.04   Max: 13.79
Current: 4.37

2.04
13.79
Share Buyback Rate 5.10
PFE's Share Buyback Rate is ranked higher than
92% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. PFE: 5.10 )
PFE' s 10-Year Share Buyback Rate Range
Min: 5.1   Max: -19
Current: 5.1

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.90
PFE's Price/DCF (Projected) is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 0.90 )
PFE' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 8.57
Current: 0.9

0.53
8.57
Price/Median PS Value 1.10
PFE's Price/Median PS Value is ranked higher than
72% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. PFE: 1.10 )
PFE' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 3.64
Current: 1.1

0.51
3.64
Price/Peter Lynch Fair Value 2.20
PFE's Price/Peter Lynch Fair Value is ranked higher than
89% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 2.20 )
PFE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.17   Max: 36.51
Current: 2.2

1.17
36.51
Earnings Yield (Greenblatt) 7.00
PFE's Earnings Yield (Greenblatt) is ranked higher than
81% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.00 vs. PFE: 7.00 )
PFE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 12.6
Current: 7

1.4
12.6
Forward Rate of Return (Yacktman) 13.98
PFE's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. PFE: 13.98 )
PFE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7.6   Max: 20.7
Current: 13.98

7.6
20.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, RHHBY, NVS, ABT » details
Traded in other countries:PFZ.UK, PFEBC.Belgium, PFE.Sweden, PFE.Switzerland, PFE.Germany
Pfizer was founded in 1849 and is a global pharmaceutical firm which develops and produces medicines and vaccines for a range of conditions which include ares of immunology, inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. Pfizer's businesses include five prescription-only biopharmaceutical businesses and Pfizer Consumer Healthcare. Primary care, Specialty Care and Oncology are responsible for life-cycle management of in-line products and new proof of concept therapies. Pfizer's Board of Directors is responsible for the oversight of management, including the overall strategic direction of the company and for the company's policies on governance, executive compensation, transparency and compliance.
» More Articles for PFE

Headlines

Articles On GuruFocus.com
Pfizer: A Fairly Valued Stock Jul 23 2014 
Although This Hedge Fund Changed Stocks in Three of Them Bet More Jul 21 2014 
Guru Favorites Top GuruFocus Dividend Growers of the Weeks Jul 01 2014 
Can Pfizer Make Up Its Loss? May 09 2014 
Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 
Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014? May 05 2014 
Wrong Marketing Lesson by Big Pharma May 03 2014 
Mario Gabelli on Bill Ackman, Valeant, AT&T, DirecTV and Pfizer May 02 2014 
Pfizer and Lockheed Martin Top Dividend Growers of the Week Apr 28 2014 
These Three Pharmaceutical Companies Shake The Market With Their Deal Apr 27 2014 

More From Our Partners
Johnson & Johnson Announces $5B Share Buyback - Analyst Blog Jul 22 2014 - ZACKS
FT: 25 More Firms May Seek Tax Breaks Overseas Jul 22 2014 - FOXBUSINESS

More From Other Websites
Guru Roundup: 10 Great Stocks To Beat The Summertime Blues Jul 23 2014
Prempro Plaintiffs’ Lawyers Settle $62 Million Fee Fight Jul 23 2014
[video] Don't Expect Tax Inversion Fever to Break Anytime Soon Jul 22 2014
Top U.S. lawmaker wants corporate tax loophole 'plugged now' Jul 22 2014
Top U.S. lawmaker wants corporate tax loophole 'plugged now' Jul 22 2014
Top U.S. lawmaker wants corporate tax loophole 'plugged now' Jul 22 2014
U.S. Senate panel to debate wave of corporate tax-avoidance deals Jul 21 2014
[video] Obstacle races attract sponsors Jul 21 2014
[video] Spartan Race eyes Olympic placement Jul 21 2014
Tax inversions allow firms to avoid state taxes Jul 21 2014
3 Stocks Reiterated As A Buy: PFE, ORCL, PEP Jul 21 2014
Bristol-Myers/Pfizer Commence Phase IV Study on Eliquis Jul 18 2014
AbbVie Is Biggest to Quit U.S. Address in $55 Billion Shire Deal Jul 18 2014
Pep Boys, Buenaventura, Pfizer, Mylan and AstraZeneca highlighted as Zacks Bull and Bear of the Day Jul 18 2014
Is Roche Eyeing Up A Bid For AstraZeneca plc? Jul 18 2014
Is Roche Eyeing Up A Bid For AstraZeneca plc? Jul 18 2014
The Hippie Hobby Lobby: Eden Foods Says No to Birth Control Jul 18 2014
Pfizer Eyes InnoPharma, Acquisition to Boost Injectables Biz Jul 17 2014
Pfizer Bolsters Injectables by Buying InnoPharma Jul 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

SEENSCO
ReplySEENSCO - 1 month ago
PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide